Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review

被引:7
|
作者
He, Weixiang [1 ]
Ding, Ting [2 ]
Niu, Zhiping [3 ]
Hao, Chunlin [1 ]
Li, Chengbin [1 ]
Xu, Zhicheng [1 ]
Jing, Yuming [1 ]
Qin, Weijun [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Lab Med, Xian, Shaanxi, Peoples R China
[3] Fudan Univ, Sch Publ Hlth, Dept Environm Hlth, Shanghai, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
benign prostate hyperplasia; lower urinary tract symptoms; surgery; retreatment; reoperation; HOLMIUM LASER ENUCLEATION; TERM-FOLLOW-UP; RANDOMIZED CONTROLLED-TRIAL; STANDARD TRANSURETHRAL RESECTION; TITANYL-PHOSPHATE LASER; URINARY-TRACT SYMPTOMS; PHOTOSELECTIVE VAPORIZATION PROSTATECTOMY; BLADDER OUTLET OBSTRUCTION; TRANSVESICAL PROSTATECTOMY; PLASMAKINETIC ENUCLEATION;
D O I
10.3389/fendo.2023.1287212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Surgical treatment is important for male lower urinary tract symptom (LUTS) management, but there are few reviews of the risks of reoperation.Objective To systematically evaluate the current evidence regarding the reoperation rates of surgical treatment for LUTS in accordance with current recommendations and guidelines.Evidence acquisition Eligible studies published up to July 2023, were searched for in the PubMed (R) (National Library of Medicine, Bethesda, MD, USA), Embase (R) (Elsevier, Amsterdam, the Netherlands), and Web of Science (TM) (Clarivate (TM), Philadelphia, PA, USA) databases. STATA (R) (StataCorp LP, College Station, TX, USA) software was used to conduct the meta-analysis. Random-effects models were used to calculate the pooled incidences (PIs) of reoperation and the 95% confidence intervals (CIs).Evidence synthesis A total of 119 studies with 130,106 patients were included. The reoperation rate of transurethral resection of the prostate (TURP) at 1, 2, 3, and 5 years was 4.0%, 5.0%, 6.0%, and 7.7%, respectively. The reoperation rate of plasma kinetic loop resection of the prostate (PKRP) at 1, 2, 3, and 5 years was 3.5%, 3.6%, 5.7%, and 6.6%, respectively. The reoperation rate of holmium laser enucleation of the prostate (HoLEP) at 1, 2, 3, and 5 years was 2.4%, 3.3%, 5.4%, and 6.6%, respectively. The reoperation rate of photoselective vaporization of the prostate (PVP) at 1, 2, 3, and 5 years was 3.3%, 4.1%, 6.7%, and 7.1%, respectively. The reoperation rate of surgery with AquaBeam (R) at 1, 2, 3, and 5 years was 2.6%, 3.1%, 3.0%, and 4.1%, respectively. The reoperation rate of prostatic artery embolization (PAE) at 1, 2, 3, and 5 years was 12.2%, 20.0%, 26.4%, and 23.8%, respectively. The reoperation rate of transurethral microwave thermotherapy (TUMT) at 1, 2, 3, and 5 years was 9.9%, 19.9%, 23.3%, and 31.2%, respectively. The reoperation rate of transurethral incision of the prostate (TUIP) at 5 years was 13.4%. The reoperation rate of open prostatectomy (OP) at 1 and 5 years was 1.3% and 4.4%, respectively. The reoperation rate of thulium laser enucleation of the prostate (ThuLEP) at 1, 2, and 5 years was 3.7%, 7.7%, and 8.4%, respectively.Conclusion Our results summarized the reoperation rates of 10 surgical procedures over follow-up durations of 1, 2, 3, and 5 years, which could provide reference for urologists and LUTS patients.Systematic review registration https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023445780.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Minimally invasive surgical therapies for benign prostatic hyperplasia in the geriatric population: A systematic review
    Abid, Ahmad
    Piperdi, Huzaifa
    Babar, Mustufa
    Loloi, Justin
    Moutwakil, Ahmed
    Azhar, Umair
    Maria, Pedro
    Small, Alexander
    PROSTATE, 2024, 84 (10) : 895 - 908
  • [2] Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review
    Baboudjian, Michael
    Cornu, Jean-Nicolas
    Gondran-Tellier, Bastien
    Fourmarier, Marc
    Robert, Gregoire
    Peyronnet, Benoit
    Misrai, Vincent
    Pradere, Benjamin
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 727 - 733
  • [3] Can surgical treatment for benign prostatic hyperplasia improve sexual function? A systematic review
    Soans, Julian
    Vazirian-Zadeh, Mahmood
    Kum, Francesca
    Dhariwal, Randeep
    Breish, Mohamed Omran
    Singh, Sohail
    Mahmalji, Wasim
    Katmawi-Sabbagh, Samer
    AGING MALE, 2020, 23 (05) : 770 - 779
  • [4] A systematic review of novel surgical treatments for benign prostatic hyperplasia
    Panayi, Zoe
    Musgrave, Hannah
    Adeyoju, Adebanji
    JOURNAL OF CLINICAL UROLOGY, 2025,
  • [5] Contemporary surgical treatment of benign prostatic hyperplasia
    Vita Nunes, Ricardo Luia
    Antunes, Alberto Azoubel
    Constantin, Davi Souza
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (08): : 711 - 716
  • [6] Benign prostatic hyperplasia (BPH). Surgical therapy options
    Reich, O.
    Seitz, M.
    Gratzke, C.
    Schlenker, B.
    Walther, S.
    Stief, C.
    UROLOGE, 2010, 49 (01): : 113 - 124
  • [7] Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift A narrative review
    Dean, Nicholas S.
    Assmus, Mark A.
    Lee, Matthew S.
    Guo, Jenny N.
    Krambeck, Amy E.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2023, 17 (10): : 353 - 359
  • [8] Review of the Economics of Surgical Treatment Options for Benign Prostatic Hyperplasia
    Aladesuru, Oluwatobi
    Punyala, Ananth
    Stoddard, Michelina
    Bhojani, Naeem
    Zorn, Kevin
    Elterman, Dean
    Chughtai, Bilal
    CURRENT UROLOGY REPORTS, 2022, 23 (01) : 11 - 18
  • [9] A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia
    Kuang, Michelle
    Vu, Anthony
    Athreya, Sriharsha
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (05) : 655 - 663
  • [10] Novel surgical techniques for treatment of benign prostatic hyperplasia
    Schoeb, D. S.
    Reichelt, A. C.
    Gross, A. J.
    Abt, D.
    Miernik, A.
    Gratzke, C.
    UROLOGE, 2020, 59 (03): : 347 - 358